Cigna earnings beat by $0.04, revenue topped estimates
NASHVILLE, TN—HCA Healthcare, Inc. (NYSE:HCA), a $92.5 billion market cap healthcare provider with strong year-to-date returns of nearly 29%, saw its Executive Vice President and Chief Operating Officer Jon Foster execute a significant stock transaction, as detailed in a recent SEC filing. On May 13, Foster sold 15,698 shares of HCA common stock at a weighted average price of $369.32 per share, totaling approximately $5.8 million. The shares were sold in multiple transactions, with prices ranging from $368.80 to $370.56.
This sale leaves Foster with direct ownership of 12,646 shares following the transaction. Additionally, the filing notes a series of non-cash transfers involving trusts, which did not alter the executive’s overall beneficial ownership of HCA shares. These transactions involved the movement of shares between family trusts and were executed at a price of $367.195 per share, reflecting the average market price on the transaction date. According to InvestingPro data, HCA maintains a GREAT financial health score, with management actively buying back shares.
The report also corrected previous administrative errors regarding indirect beneficial ownership held in the JMF Family Trust. Based on InvestingPro’s Fair Value analysis, HCA currently trades near its Fair Value, with 8 additional ProTips and comprehensive metrics available to subscribers.
In other recent news, HCA Healthcare reported a strong first quarter in 2025, with earnings per share reaching $6.45, surpassing analyst expectations of $5.78. The company’s revenue also exceeded forecasts, totaling $18.32 billion against a predicted $18.26 billion. Despite these positive results, HCA’s stock experienced a decline in pre-market trading, which may reflect broader market concerns. KeyBanc Capital Markets maintained an Overweight rating on HCA with a $370 target, praising the company’s robust same-store sales growth and effective expense management. Meanwhile, BofA Securities raised its price target for HCA to $410, citing strong demand for services and effective cost management. RBC Capital Markets, however, reduced its price target to $376, acknowledging policy uncertainties affecting the healthcare sector. Additionally, HCA Healthcare announced updates to its Board of Directors compensation and amendments to its stock incentive plan, reflecting its commitment to aligning executive compensation with company performance and shareholder interests.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.